Sogroya (somapacitan-beco) is now approved as the first once-weekly, long-acting human growth hormone option for pediatric patients aged 2.5 years and older with growth failure associated with Turner ...
Reduction in perioperative hypotension seen among older adults undergoing noncardiac surgery under general anesthesia ...
Intrathecal adrabetadex reduced the risk of death by 55% compared with weighted external controls in patients whose ...
In the phase 3 TroFuse-015 study, sacituzumab tirumotecan significantly improved overall survival compared with physician’s choice of chemotherapy in pretreated advanced gastroesophageal ...
Priority Review for the investigational CLDN18.2-directed antibody-drug conjugate is supported by phase 3 CLARITY-Gastric01 overall survival data, with an FDA decision expected in the second quarter ...
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
Oral remibrutinib demonstrated early and sustained efficacy through 52 weeks across 3 CIndU subtypes in the phase 3 RemIND ...
A survey presented at ACAAI 2026 shows 77% of US allergists attempt to wean patients off asthma biologics after sustained ...
An ACAAI 2026 retrospective study shows allergists and immunologists most often diagnose chronic spontaneous urticaria.
Research presented at ACAAI 2026 evaluates stock versus personal epinephrine supply requirements, epinephrine availability, ...
HealthDay News — In July to August 2025, about one in 10 US adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research ...